Article ; Online: Recent advances in cytomegalovirus infection management in solid organ transplant recipients.
Current opinion in organ transplantation
2024 Volume 29, Issue 2, Page(s) 131–137
Abstract: Purpose of review: Human cytomegalovirus (CMV) continues to be the most important infectious complication following solid organ transplantation (SOT).: Recent findings: Universal prophylaxis and preemptive therapy are the most adopted strategies for ... ...
Abstract | Purpose of review: Human cytomegalovirus (CMV) continues to be the most important infectious complication following solid organ transplantation (SOT). Recent findings: Universal prophylaxis and preemptive therapy are the most adopted strategies for prevention of CMV disease globally. Prophylaxis with valganciclovir is the most widely used approach to CMV prevention, however leukopenia and late onset CMV disease after discontinuation of prophylaxis requires new strategies to prevent this complication. The use of assays detecting CMV-specific T cell-mediated immunity may individualize the duration of antiviral prophylaxis after transplantation. Letermovir has been recently approved for prophylaxis in kidney transplant recipients. CMV-RNAemia used together with CMV-DNAemia in the viral surveillance of CMV infection provides accurate information on viral load kinetics, mostly in patients receiving letermovir prophylaxis/therapy. The development of refractory and resistant CMV infection remains a major challenge and a new treatment with maribavir is currently available. In the present paper we will review the most recent advances in prevention and treatment of CMV diseases in SOT recipients. Summary: Recent findings, summarized in the present paper, may be useful to optimize prevention and treatment of CMV infection in SOT. |
---|---|
MeSH term(s) | Humans ; Antiviral Agents/therapeutic use ; Cytomegalovirus Infections/diagnosis ; Cytomegalovirus Infections/drug therapy ; Cytomegalovirus Infections/prevention & control ; Valganciclovir/therapeutic use ; Transplant Recipients ; Organ Transplantation/adverse effects ; Acetates ; Quinazolines |
Chemical Substances | letermovir (1H09Y5WO1F) ; Antiviral Agents ; Valganciclovir (GCU97FKN3R) ; Acetates ; Quinazolines |
Language | English |
Publishing date | 2024-01-30 |
Publishing country | United States |
Document type | Review ; Journal Article |
ZDB-ID | 1390429-2 |
ISSN | 1531-7013 ; 1087-2418 |
ISSN (online) | 1531-7013 |
ISSN | 1087-2418 |
DOI | 10.1097/MOT.0000000000001139 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5609: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.